DR. RAMI S OWERA M.D. NPI 1659399624

NPI Details

DR. Rami S Owera, M.D. is a hematology and oncology internal medicine in Pensacola, FL with 30 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. DR. Rami S Owera, M.D. NPI is 1659399624. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

The provider's business location address is:

4724 N DAVIS HWY
PENSACOLA, FL
ZIP 32503-339
Phone: (850) 696-4000
Fax: (850) 432-2532

The NPI 1659399624 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram (HCPCS:Q5101)
• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, azacitidine, 1 mg (HCPCS:J9025)
• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, paclitaxel protein-bound particles, 1 mg (HCPCS:J9264)
• Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml (HCPCS:Q9967)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg (HCPCS:Q5118)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units (HCPCS:Q5106)
• Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1568)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Injection, fulvestrant, 25 mg (HCPCS:J9395)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection, gadobenate dimeglumine (multihance), per ml (HCPCS:A9577)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Injection, pegfilgrastim-bmez, biosimilar, (ziextenzo), 0.5 mg (HCPCS:Q5120)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Nuclear medicine study from skull base to mid-thigh with ct scan (HCPCS:78815)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries (HCPCS:A9552)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• Ct scan of abdomen and pelvis with contrast (HCPCS:74177)
• Ct scan of chest with contrast (HCPCS:71260)
• Blood creatinine level (HCPCS:82565)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) (HCPCS:G0279)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Ct scan of chest without contrast (HCPCS:71250)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Diagnostic mammography of both breasts (HCPCS:77066)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Initial hospital inpatient care per day, typically 50 minutes (HCPCS:99222)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Mri scan of brain before and after contrast (HCPCS:70553)
• Screening mammography (HCPCS:77067)
• Dxa bone density measurement of hip, pelvis, spine (HCPCS:77080)
• Injection of drug or substance into vein (HCPCS:96374)
• Screening 3d breast mammography (HCPCS:77063)
• Diagnostic mammography of 1 breast (HCPCS:77065)
• Collection of blood sample from implanted device (HCPCS:36591)
• Mri scan of abdomen before and after contrast (HCPCS:74183)
• Complete ultrasound scan of 1 breast (HCPCS:76641)
• Limited ultrasound scan of 1 breast (HCPCS:76642)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional (HCPCS:99211)
• Ct scan of abdomen and pelvis without contrast (HCPCS:74176)
• X-ray of chest, 2 views (HCPCS:71046)
• Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and (HCPCS:G0180)
• Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries (HCPCS:A9503)
• Nuclear medicine study of bone and/or joint whole body (HCPCS:78306)

The enumeration date for this NPI number is 7/18/2006 and was last updated on 6/15/2016.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.